The Problem of Aducanumab for the Treatment of Alzheimer Disease

The FDA's decision to approve aducanumab for the treatment of Alzheimer’s disease is among its most controversial ever. This commentary examines the decision's implications for clinical research and patient care.

Annals of Internal Medicine